Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-26 @ 4:02 AM
Study NCT ID:
NCT00220194
Status:
COMPLETED
Last Update Posted:
2016-10-14
First Post:
2005-09-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Sponsor:
San Bernardino Urological Associates Medical Group Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2003-04
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2005-06
Completion Date Type:
None
First Submit Date:
2005-09-17
First Submit QC Date:
None
Study First Post Date:
2005-09-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-10-13
Last Update Post Date:
2016-10-14
Last Update Post Date Type:
ESTIMATED